Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2004

View Archived Issues

Fluvastatin XL reduces coronary artery disease risk factor in diabetic patients

Protective effects of palifermin during chemotherapy/radiotherapy

Two series of DPP-IV inhibitors prepared and tested at Tanabe Seiyaku

Pfizer describes new CDK2/CDK4 inhibitors with utility in cancer therapy

Novartis and Scripps jointly describe new antitumor epothilones

Two novel series of GABA-A receptor ligands developed at Merck

New GSK-3beta inhibitors in early development at Mitsubishi Pharma

New tyrosine kinase inhibitors emerge from Merck R&D

Monoclonal antibody with broad HIV-neutralizing activity identified by NIH and NCI

Targeting IkappaB kinase for inflammation and pain therapy

European Commission approves extended labeling for Xenical

Positive phase III results for Velac

Allowance of IND for clinical testing of new HIV vaccine

Structural GenomiX enters drug discovery collaboration with Serono

Norak BioSciences completes screening collaboration with Sumitomo

IND filing for DB-289 as oral treatment for African sleeping sickness

Health Discovery and U. of Miami enter AIDS-related dementia agreement

Pamorelin LA receives approval in Germany

Orphan drug status for sodium thiosulfate

Encouraging preclinical data reported for glucosylceramide

European orphan drug status for Anatibant

New European phase II/III trial for Bexidem in bladder cancer

INDs filed for topical PEP-005

Fosrenol receives approval in Sweden

Comparative monkey studies successfully completed for Belerofon

Phase III results for anidulafungin plus liposomal amphotericin B

Interim data from HuMax-IL-15 phase II study in RA

Doxycycline hyclate reported safe and effective for rosacea

Effective maintenance of asthma control with a fluticasone propionate/salmeterol combination

Improved asthma control achieved with Symbicort single inhaler therapy

Olopatadine significantly improves the quality of life of patients with SAR

Low incidence of oropharyngeal side effects found with ciclesonide in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...